Ritzman Pharmacies in talks to own Buehler’s pharmacies
WADSWORTH, Ohio — Ritzman Pharmacies and Buehler Food Markets on Wednesday announced a letter of intent to explore a potential business partnership in which Ritzman would own and operate all of Buehler’s 11 pharmacies.
"Our focus is on our customers and the assurance to receive the same service they have come to expect," stated Dan Buehler, president of Buehler’s Fresh Foods.
Following these negotiations, a formal announcement is expected sometime this fall.
Ritzman operates nine pharmacies, known for a commitment to supporting the communities they serve. Ritzman also specializes in Ritzman brand supplements, a complete line of high-quality supplements.
Buehler’s operates 13 supermarket locations in all.
Lower concentrations of flu drug will be available, FDA says
SILVER SPRING, Md. — A new formulation of a common drug for flu will be available in lower concentrations to reduce the possibility of medication errors, the Food and Drug Administration said Wednesday.
The FDA said the change applies to the oral suspension form of Genentech’s Tamiflu (oseltamivir). The formulation is a powder that the pharmacist mixes with water to make it easier to take for patients who have difficulty swallowing capsules.
The change was made because the higher-concentration version becomes frothy when mixed, making it more difficult to measure the correct dose.
Studies find HIV drug treatments may reduce infection risk among heterosexual couples
NEW YORK — Taking drugs for treating HIV might reduce the risk of infection among heterosexual couples, according to two new studies conducted in Africa.
One study, funded by the Bill & Melinda Gates Foundation and conducted among 4,758 couples in Kenya and Uganda, found that when taken daily, Gilead’s Viread (tenofovir) reduced the rates of infection by at least 62% compared with placebo. Truvada (tenofovir and emtricitabine), another drug made by Gilead, reduced infection risk by 73%.
In the second study, 1,219 sexually active men and women in Botswana were given Truvada, which was found to cut their HIV infection risk by 62.6%.
The studies were designed to evaluate pre-exposure prophylaxis, or PrEP, whereby people take HIV drugs to prevent infection. But PrEP studies have had mixed results. In an earlier PrEP study of 2,000 women in Africa, Truvada did not appear to offer protection.
In a study published in the New England Journal of Medicine in November 2010, researchers evaluated Truvada PrEP in 2,470 gay and bisexual men and 29 transgender women who had sex with men in the United States, South Africa, Thailand, Brazil, Ecuador and Peru; that study found that PrEP reduced the risk of HIV infection by 44%.